The cause and treatment of vitreous rebleeding after vitrectomy for proliferative diabetic retinopathy

doi:10.3877/cma.j.issn.2095-2007.2017.06.006

Abstract

Abstract:

Objective

To study the causes of vitreous reaccumulation of blood after vitrectomy for proliferative diabetic retinopathy (PDR), and to analyze the corresponding treatment methods.

Methods

The clinical data of 30 cases (30 eyes) of PDR in the Department of Ophthalmology of Chifeng Second Hospital of Inner Mongolia from April 2016 to 2017 were selected for 4 menstruation. Vitrectomy was performed in all patients with vitreous reaccumulation of blood. All the patients with vitrectomy with vitrectomy after PDR were analyzed, and the therapeutic effect was observed and the prognosis was observed. 23 cases (23 eyes) with normal intraocular pressure and no retinal detachment were treated with conservative treatment. They were given oral or intramuscular injection of hemostatic drugs and Chinese herbs for promoting blood circulation and removing blood stasis. 7 cases (7 eyes) with retinal detachment were treated with vitreoretinal surgery.

Results

The reason for PDR patients in postoperative vitreous body hematocele and vitreous body symptoms are mainly in the following aspects, three channel resection of sclera incision in the vitreous body neovascularization occurred in 10 cases (10 eyes), the total number of eyes 33.33%; 5 cases (5 eyes) of residual membrane vascular stump hemorrhage, the total number of eyes 16.67%; retinal or optic disc neovascularization and hemorrhage in 8 cases (8 eyes), the total number of eyes 26.67%; 3 cases (3 eyes) of retinal vein occlusion, the total number of eyes 10.00%; 4 cases (4 eyes) of otherwise unexplained patients, the total number of eyes 13.33%. Time with vitreous body hematocele and different patients with vitreous body after resection, 14 cases (14 eyes) a week after surgery, the total number of eyes 46.67% after silicone oil removal; concurrent 6 cases (6 eyes), the total number of eyes 20.00% after silicone oil removal; 1 months with 5 cases (5 eyes), the total number of eyes 16.67%; 3 months after silicone oil removal with 5 cases (5 eyes), the total number of eyes 16.67%. All patients were followed up. 6 months after treatment, 23 cases (23 eyes) were conservatively treated. 20 cases (20 eyes) had no blood loss. 3 cases (3 eyes) who had no conservative treatment were required to undergo vitreoretinal surgery. In 7 cases (7 eyes) with retinal detachment, all blood disappeared after vitreoretinal surgery.

Conclusion

The main reason for PDR patients complicated with vitreous body after resection of vitreous body hematocele three channel and resection of sclera incision in vitreous body, residual neovascularization membrane vascular stump hemorrhage, retinal hemorrhage or disc neovascularization and retinal vein occlusion, clinically according to the specific circumstances of the patients for targeted treatment, in order to improve the prognosis in patients.

Key words: Proliferative diabetic retinopathy, Vitrectomy, Vitreous reaccumulation of blood

Weidong Liu, Henan Bai, Ran Bi, Dan Zhu. The cause and treatment of vitreous rebleeding after vitrectomy for proliferative diabetic retinopathy[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2017, 07(06): 269-274.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2017.06.006

https://zhykyxzz.cma-cmc.com.cn/EN/Y2017/V07/I06/269

References 80

[1]	仇长宇,石圆圆,潘朝阳, 等. 糖尿病视网膜病变患者视网膜中央动脉血流与术后视力改善的关系[J]. 临床超声医学杂志, 2017, 19(10): 656-658.
[2]	王方,冯乐,惠延年. 视网膜光凝和玻璃体手术治疗糖尿病视网膜病变的有效性[J]. 眼科新进展, 2012, 32(10): 901-904.
[3]	Listed N. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial－Diabetic Retinopathy Vitrectomy Study Report 4[J]. Ophthalmology, 1988, 95(10): 1321-1334.
[4]	Listed N. Two－year course of visual acuity in severe proliferative diabetic retinopathy with conventional management[J]. Ophthalmology, 1985, 92(4): 492-502.
[5]	孟丽珠,陈松,赵秉水, 等. 玻璃体视网膜手术治疗增生性糖尿病视网膜病变合并牵拉性视网膜脱离视力预后影响因素[J]. 中华眼底病杂志, 2010, 26(2): 124-127.
[6]	朴天华,张召弟,杨岚, 等. 玻璃体腔内注射康柏西普联合玻璃体切除术治疗增殖性糖尿病视网膜病变的临床效果[J]. 海峡药学, 2016, 28(9): 95-97.
[7]	冉起,冯驰,周文娟. 康柏西普辅助玻璃体切除术治疗糖尿病视网膜病变[J]. 中国医药导刊, 2016, 18(7): 708-709.
[8]	孟娜,任百超. 贝伐单抗玻璃体腔注射对PDR伴玻璃体积血的治疗效果[J]. 国际眼科杂志, 2016, 16(5): 972-974.
[9]	王雨晴,张招德,余铮, 等. 玻璃体切割术联合口服荧光素钠治疗增殖性糖尿病视网膜病变[J]. 海南医学, 2016, 27(5): 812-813.
[10]	李洋. 玻璃体腔注射雷珠单抗与曲安奈德在辅助玻璃体切除术治疗增殖性糖尿病视网膜病变中的对比研究[D]. 郑州：郑州大学，2016.
[11]	Ozaki H,Seo MS,Ozaki K, et al. Blockade of Vascular Endothelial Cell Growth Factor Receptor Signaling Is Sufficient to Completely Prevent Retinal Neovascularization[J]. American Journal of Pathology, 2000, 156(2): 697-707.
[12]	Skopinski P,Szaflik J,Dudakról B, et al. Suppression of angiogenic activity of sera from diabetic patients with non－proliferative retinopathy by compounds of herbal origin and sulindac sulfone[J]. International Journal of Molecular Medicine, 2004, 14(4): 707-711.
[13]	Malecaze F,Clamens S,Simorre－Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor－like activity in proliferative diabetic retinopathy[J]. Arch Ophthalmol, 1994, 112(11): 1476-1482.
[14]	Buchdunger E,Zimmermann J,Mett H, et al. Selective inhibition of the platelet－derived growth factor signal transduction pathway by a protein－tyrosine kinase inhibitor of the 2－phenylaminopyrimidine class[J]. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92(7): 2558-2562.
[15]	Adamis AP,Shima DT,Tolentino MJ, et al. Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia－Associated Iris Neovascularization in a Nonhuman Primate[J]. Arch Ophthalmol, 1996, 114(1): 66-71.
[16]	Iwase T,Oveson BC,Hashida N, et al. Topical pazopanib blocks VEGF\\induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit[J]. Invest Ophthalmol Vis Sci, 2013, 54(1): 503-511.
[17]	Kinnunen K,Korpisalo P,Rissanen TT, et al. Overexpression of VEGF－A induces neovascularization and increased vascular leakage in rabbit eye after intravitreal adenoviral gene transfer[J]. Acta Physiologica, 2006, 187(4): 447-457.
[18]	俞学群,曹国平,汤明霞. 玻璃体切除术联合药物治疗增殖性糖尿病视网膜病变的疗效[J]. 国际眼科杂志, 2015, 15(8): 1402-1404.
[19]	张扬,戴荣平,卞爱玲. 玻璃体腔注射雷珠单抗对增殖性糖尿病视网膜病变手术的影响[J]. 国际眼科杂志, 2015, 15(8): 1450-1454.
[20]	Li B,Sharpe EE,Maupin AB, et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization[J]. Faseb Journal Official Publication of the Federation of American Societies for Experimental Biology, 2006, 20(9): 1495-1497.
[21]	计岩,赵敏. 贝伐单抗辅助玻璃体切除术治疗增生性糖尿病视网膜病变疗效的系统评价[J]. 重庆医科大学学报, 2013, 38(12): 1476-1481.
[22]	王颖,阿子古力·沙木沙克,于继, 等. 玻璃体切割联合白内障手术治疗增殖性糖尿病视网膜病变中的疗效[J]. 现代生物医学进展, 2017, 17(25): 4959-4962.
[23]	Arevalo JF,Maia M,Flynn HW, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy[J]. Bri J Ophthalmol, 2008, 92(2): 213-216.
[24]	Zhao LQ,Zhu H,Zhao PQ, et al. A systematic review and meta－analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy[J]. Bri J Ophthalmol, 2011, 95(9): 1216-1222.
[25]	Cheema RA,Mushtaq J,Al－Khars W, et al. Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage[J]. Retina, 2010, 30(10): 1646-1650.
[26]	Rosenfeld PJ,Fung AE,Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion[J]. Dkgest of the World Latest Medical Information, 2005, 36(4): 336-339.
[27]	孙荻芳. 糖尿病性视网膜病变玻璃体切除术后渗出性视网膜脱离相关因素分析[D]. 长春：吉林大学，2017.
[28]	仇长宇,伍春荣,罗灵, 等. 玻璃体注药联合微创玻璃体切除治疗增殖性糖尿病视网膜病变的临床应用研究[J]. 解放军医药杂志, 2016, 28(9): 5-7.
[29]	李志强. 玻璃体切除术治疗增殖期视网膜病变的临床研究[J]. 中国医药科学, 2016, 6(12): 210-212.
[30]	李月礼. 增殖性糖尿病视网膜病变玻璃体切除术的效果观察[J]. 河南外科学杂志, 2016, 22(3): 126-127.
[31]	Kaiser RS,Maguire MG,Grunwald JE, et al. One－year outcomes of panretinal photocoagulation in proliferative diabetic retinopathy[J]. Am J Ophthalmol, 2000, 129(2): 178-185.
[32]	Preti RC,Ramirez LM,Monteiro ML, et al. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial[J]. Bri J Ophthalmol, 2013, 97(7): 885-889.
[33]	Yong WS,Lee YJ,Lee BR, et al. Effects of an Intravitreal Bevacizumab Injection Combined With Panretinal Photocoagulation on High－Risk Proliferative Diabetic Retinopathy[J]. Korean Journal of Ophthalmology Kjo, 2009, 23(4): 266-272.
[34]	Takamura Y,Tomomatsu T,Matsumura T, et al. Photocoagulation for peripheral nonperfusion－areas to prevent the recurrence of diabetic macular edema after single intravitreal injection of bevacizumab[J]. Shikai tenbo, 2013, 64(3): 519-526.
[35]	Michaelides M,Kaines A,Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12－month data: report 2[J]. Ophthalmology, 2010, 117(6): 1078-1086.
[36]	李丽,关新辉,易湘龙. 联合手术治疗增殖性糖尿病视网膜病变的继发性新生血管性闭角型青光眼[J]. 国际眼科杂志, 2016, 16(5): 938-941.
[37]	蔡玲,崔建怡. 严重增殖性糖尿病视网膜病变玻璃体切除术后视功能评价[J]. 国际眼科杂志, 2016, 16(4): 633-637.
[38]	郭翠玲,赵仲平,廖继波, 等. 玻璃体切除术治疗增殖性糖尿病视网膜病变的临床研究[J]. 海南医学, 2016, 27(2): 216-218.
[39]	康克明,吴国基. 玻璃体切割视网膜复位术与抗新生血管药物联合治疗严重增殖性糖尿病视网膜病变分析[J]. 中外医疗, 2015, 34(35): 33-34.
[40]	Moshfeghi AA,Rosenfeld PJ,Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age－related macular degeneration: twenty－four－week results of an uncontrolled open－label clinical study[J]. Ophthalmology, 2005, 112(6): 1035-1047.
[41]	Laupacis A,Feeny D,Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations[J]. Cmaj, 1992, 146(4): 473-481.
[42]	张萃丽,郁梅,陈雪艺. 老年增殖性糖尿病视网膜病变手术治疗的回顾性分析[J]. 国际眼科杂志, 2015, 15(11): 1996-1998.
[43]	孙梅,李明新. 糖尿病视网膜病变围手术期的抗VEGF研究[J]. 国际眼科杂志, 2015, 15(10): 1772-1774.
[44]	许丹,孔令磷. 音乐疗法对增殖性糖尿病视网膜病变玻璃体切除术后舒适度的影响[J]. 湖北科技学院学报(医学版), 2015, 29(4): 293-295.
[45]	赖江峰. 增殖性糖尿病视网膜病变的玻璃体切除手术治疗[J]. 中国医药科学, 2015, 5(14): 195-197.
[46]	周林,姚进. 增殖性糖尿病性视网膜病变玻璃体切割术后高眼压的研究[J]. 眼科新进展, 2015, 35(1): 74-77.
[47]	孙力,张燕钦,钟玉红. 不同病变程度增殖性糖尿病视网膜病变行玻璃体手术的临床比较[J]. 现代诊断与治疗, 2014, 25(24): 5625-5626.
[48]	郦晓霞，吴苗琴. 严重增殖性糖尿病视网膜病变23G玻璃体切除联合硅油填充术后临床观察[C]．浙江省眼科学术年会论文汇编，2014.
[49]	冯会芳. 玻璃体切除联合硅油填充并全视网膜激光光凝术治疗Ⅴ期糖尿病视网膜病变[J]. 医药论坛杂志, 2014, 35(11): 96-97.
[50]	韩敬牧. 用玻璃体切除术联合白内障超声乳化吸除术治疗增殖性糖尿病视网膜病变的效果探析[J]. 当代医药论丛, 2014, 12(19): 221-222.
[51]	李云环. 玻璃体切除联合白内障摘除治疗糖尿病视网膜病变术后角膜上皮功能受损的问题思考[C]. 世界中医药学会联合会眼科专业委员会国际眼科学术研讨会，2014.
[52]	詹冬梅,哈玲芳,李娜, 等. 增殖性糖尿病视网膜病变联合手术治疗的应用研究[J]. 宁夏医学杂志, 2014, 36(10): 879-881.
[53]	黎作为,冯小志,黎容. 手术治疗增殖性糖尿病视网膜病变68例临床观察[J]. 现代临床医学, 2014, 40(3): 194-196.
[54]	张彦来,官思远. 糖尿病视网膜病变手术后继发新生血管青光眼的危险因素[J]. 重庆医科大学学报, 2014, 39(8): 1110-1113.
[55]	黄少萍,张小妮,张良. 增殖性糖尿病视网膜病变玻璃体切割术后高眼压的护理[J]. 现代临床护理, 2014, 13(1): 35-37.
[56]	周静,梁丽琼,程军英, 等. 玻璃体切除术治疗增殖性糖尿病视网膜病变的疗效观察[J]. 甘肃医药, 2013, 32(12): 895-897.
[57]	齐慧君. 抗血管内皮生长因子疗法在眼科中的应用[J/CD]. 中华眼科医学杂志(电子版), 2017, 7(2): 49-59.
[58]	袁莉娟,史爱欣,傅得兴. 兰尼单抗的药理作用及临床评价[J]. 中国新药杂志, 2008, 17(13): 1172-1175.
[59]	杨涛,项振扬,郑玥. 玻璃体切割术中与术后行全视网膜激光光凝治疗增殖性糖尿病性视网膜病变效果[J]. 中国乡村医药, 2013, 20(22): 46-47.
[60]	沈毅,肖静,何书, 等. 增殖性糖尿病视网膜病变眼科手术前后的生存质量及其影响因素分析[J]. 现代预防医学, 2013, 40(18): 3337-3339.
[61]	周卓琳,毕春潮,王睿. 合并玻璃体积血的糖尿病视网膜病变患者的手术治疗分析[J]. 国际眼科杂志, 2013, 13(8): 1648-1650.
[62]	苏丹,李虹霓,李洪龙. 玻璃体切除术治疗增殖性糖尿病视网膜病变的疗效观察[J]. 中国现代医生, 2013, 51(22): 14-15.
[63]	刘洁梅,黄中宁,尹东明, 等. 增殖性糖尿病视网膜病变多次手术临床分析[J]. 国际眼科杂志, 2012, 12(11): 2201-2203.
[64]	梅锋,周琼. 增殖性糖尿病视网膜病变的玻璃体切除术的疗效分析[J]. 中国现代医学杂志, 2012, 22(18): 107-109.
[65]	Goldstein DE,Blinder KJ,Ide CH, et al. Glycemic control and development of retinopathy in youth－onset insulin－dependent diabetes mellitus. Results of a 12－year longitudinal study[J]. Ophthalmology, 1993, 100(8): 1125-1131.
[66]	Little RR,Goldstein DE. A commercially available paper sample collection method for measuring glycated hemoglobin evaluated: are all of these people diabetic？[J]. Clinical Chemistry, 1986, 32(5): 898.
[67]	Weber B,Burger W,Hartmann R, et al. Risk factors for the development of retinopathy in children and adolescents with Type 1 (insulin－dependent) diabetes mellitus[J]. Diabetologia, 1986, 29(1): 17-22.
[68]	Keiding NR,Mann GV,Root HF, et al. Serum lipoproteins and cholesterol levels in normal subjects and in young patients with diabetes in relation to vascular complications[J]. Diabetes, 1952, 1(1): 434-440.
[69]	Jensen T,Stender S,Deckert T. Abnormalities in plasmas concentrations of lipoproteins and fibrinogen in Type 1 (insulin－dependent) diabetic patients with increased urinary albumin excretion[J]. Diabetologia, 1988, 31(3): 142-145.
[70]	Lopes AAB,Maeda NY,Aiello VD, et al. Abnormal Multimeric and Oligomeric Composition Is Associated With Enhanced Endothelial Expression of von Willebrand Factor in Pulmonary Hypertension[J]. Chest, 1993, 104(5): 1455-1460.
[71]	Maser RE,Jr WS,Ellis D, et al. Cardiovascular disease and arterial calcification in insulin－dependent diabetes mellitus: interrelations and risk factor profiles. Pittsburgh Epidemiology of Diabetes Complications Study－V[J]. Arterioscler Thromb, 1991, 11(4): 958-965.
[72]	Morrish NJ,Stevens LK,Head J, et al. A prospective study of mortality among middle－aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) Ⅱ：Associated risk factors[J]. Diabetologia, 1990, 33(9): 542-548.
[73]	Organization WH. Manual of the international statistical classification of diseases, injuries, and causes of death: based on the recommendations of the seventh revision Conference, 1955, and adopted by the ninth World Health Assembly under the WHO Nomenclature Regulations[J]. Bulletin of the World Health Organization, 1957, 240(4): 90.
[74]	Sellers AH. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death.[J]. Canadian Journal of Public Health, 1949, 2(8): 366-367.
[75]	Valmadrid CT,Klein R,Moss SE, et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older－onset diabetes mellitus[J]. Archives of Internal Medicine, 2000, 160(8): 1093-1100.
[76]	Jassal SK,Langenberg C,Mühlen DV, et al. Usefulness of Microalbuminuria vs. the Metabolic Syndrome as a Predictor of Cardiovascular Disease in Women and Men>40 Years of Age (From the Rancho Bernardo Study)[J]. American Journal of Cardiology, 2008, 101(9): 1275-1280.
[77]	Mabuchi H,Kita T,Matsuzaki M, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low－dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the J[J]. Circulation Journal Official, 2002, 66(12): 1096-1100.
[78]	Chao D,Du ZD,Yu W, et al. Effect of pravastatin on endothelial dysfunction in children with medium to giant coronary aneurysms due to Kawasaki disease[J]. World Journal of Pediatrics Wjp, 2014, 10(3): 232-237.
[79]	Pedersen TR,Olsson AG,Færgeman O, et al. Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)[J]. Atherosclerosis Supplements, 1998, 97(15): 1453-1460.
[80]	Lamarche B,Moorjani S,Lupien PJ, et al. Apolipoprotein A－I and B Levels and the Risk of Ischemic Heart Disease During a Five－Year Follow－up of Men in the Que'bec Cardiovascular Study[J]. Circulation, 1996, 94(3): 273-278.

Please choose a citation manager

Content to export